Multiple Kinase Small Molecule Inhibitor Tinengotinib (TT-00420) Alone or With Chemotherapy Inhibit the Growth of SCLC.

Cancer Sci · 2025 · PMC11967258 · PMID 39817471

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

However, H2227 showed an increasing trend in IC 50 values, but this was not statistically significant ( p = 0.12; p = 0.17).

also in 38,133 other papers

a notable trendno p-value reported

Nevertheless, our study demonstrated that tinengotinib inhibits SCLC growth, and its combination with EP exhibits a notable trend of synergistic inhibition of SCLC growth.

also in 2,135 other papers

a decreasing trendno p-value reported

The EP group showed a decreasing trend at 24 h and decreased significantly at 48 h ( p = 0.0257) (Figure 2E ).

also in 29,876 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.